KalVista Pharmaceuticals, Inc. (KALV) financial statements (2022 and earlier)

Company profile

Business Address 55 CAMBRIDGE PARKWAY
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End April 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

1/31/2022
TTM
4/30/2021
4/30/2020
4/30/2019
4/30/2018
4/30/2017
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments194,789248,92967,714100,81151,05530,95053,723
Cash and cash equivalents45,57750,59215,78932,00651,05530,95053,723
Short-term investments149,212198,33751,92568,805   
Receivables    6,8342,547 
Other undisclosed current assets19,67515,33520,98214,7351,4917511,222
Total current assets:214,464264,26488,696115,54659,38034,24854,945
Noncurrent Assets
Operating lease, right-of-use asset8,1805,7581,612
Property, plant and equipment2,2151,7912,0432,4131,83697805
Restricted cash and investments      50
Other noncurrent assets193200178173173 991
Total noncurrent assets:10,5887,7493,8332,5862,009971,846
TOTAL ASSETS:225,052272,01392,529118,13261,38934,34556,791
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,6358,9117,1328,4534,5203,0182,787
Accounts payable2,1851,9811,6772,8601,4331,1531,460
Accrued liabilities6,4506,9305,4555,5933,0871,8651,327
Debt  58854221 1,455
Deferred revenue and credits  29
Contract with customer, liability9,545
Other undisclosed current liabilities1,014863  18,475  
Total current liabilities:9,6499,7747,72018,05223,2163,0184,271
Noncurrent Liabilities
Long-term debt and lease obligation7,4675,0461,057 58 3,154
Long-term debt, excluding current maturities      3,154
Capital lease obligations 58  
Operating lease, liability7,4675,0461,057
Liabilities, other than long-term debt   3,342  56
Deferred revenue and credits  56
Contract with customer, liability3,342
Other undisclosed noncurrent liabilities(7,467)(5,046)  10,862  
Total noncurrent liabilities:7,4675,0461,0573,34210,920 3,210
Total liabilities:17,11614,8208,77721,39434,1363,0187,481
Stockholders' equity
Stockholders' equity attributable to parent207,936257,19383,75296,73827,25331,32749,310
Common stock24241817111027
Additional paid in capital436,313426,437207,208191,123100,01189,815121,904
Accumulated other comprehensive loss(2,339)(1,432)(1,882)(1,926)(1,109)(2,643) 
Accumulated deficit(226,062)(167,836)(121,592)(92,476)(71,660)(55,855)(72,621)
Total stockholders' equity:207,936257,19383,75296,73827,25331,32749,310
TOTAL LIABILITIES AND EQUITY:225,052272,01392,529118,13261,38934,34556,791

Income statement (P&L) ($ in thousands)

1/31/2022
TTM
4/30/2021
4/30/2020
4/30/2019
4/30/2018
4/30/2017
12/31/2015
Revenues  12,69016,1278,3941,50429
Revenue, net 1,50429
Gross profit:  12,69016,1278,3941,50429
Operating expenses(87,844)(57,923)(53,223)(45,947)(27,099)(23,843)(21,065)
Operating loss:(87,844)(57,923)(40,533)(29,820)(18,705)(22,339)(21,036)
Nonoperating income (expense)14,66211,67911,2939,1282,9003,736(3,810)
Investment income, nonoperating1,1369031,8301,39782365
Foreign currency transaction gain (loss), before tax(397)847(367)49(1,574)1,371 
Other nonoperating income13,9239,9299,8307,6824,3922,329550
Interest and debt expense      (3,177)
Loss from continuing operations before income taxes:(73,182)(46,244)(29,240)(20,692)(15,805)(18,603)(28,023)
Income tax expense (benefit)  124(124)   
Net loss:(73,182)(46,244)(29,116)(20,816)(15,805)(18,603)(28,023)
Other undisclosed net income attributable to parent      3,177
Net loss available to common stockholders, diluted:(73,182)(46,244)(29,116)(20,816)(15,805)(18,603)(24,846)

Comprehensive Income ($ in thousands)

1/31/2022
TTM
4/30/2021
4/30/2020
4/30/2019
4/30/2018
4/30/2017
12/31/2015
Net loss:(73,182)(46,244)(29,116)(20,816)(15,805)(18,603)(28,023)
Other comprehensive income (loss)(1,072)450     
Comprehensive loss:(74,254)(45,794)(29,116)(20,816)(15,805)(18,603)(28,023)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  44(817)1,534(2,568) 
Comprehensive loss, net of tax, attributable to parent:(74,254)(45,794)(29,072)(21,633)(14,271)(21,171)(28,023)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: